ImmunovantInc Cash Flow Coverage Ratios vs Net Income Per E B T Analysis
IMVT Stock | USD 27.17 0.58 2.09% |
ImmunovantInc financial indicator trend analysis is infinitely more than just investigating ImmunovantInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunovantInc is a good investment. Please check the relationship between ImmunovantInc Cash Flow Coverage Ratios and its Net Income Per E B T accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.
Cash Flow Coverage Ratios vs Net Income Per E B T
Cash Flow Coverage Ratios vs Net Income Per E B T Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunovantInc Cash Flow Coverage Ratios account and Net Income Per E B T. At this time, the significance of the direction appears to have very week relationship.
The correlation between ImmunovantInc's Cash Flow Coverage Ratios and Net Income Per E B T is 0.2. Overlapping area represents the amount of variation of Cash Flow Coverage Ratios that can explain the historical movement of Net Income Per E B T in the same time period over historical financial statements of ImmunovantInc, assuming nothing else is changed. The correlation between historical values of ImmunovantInc's Cash Flow Coverage Ratios and Net Income Per E B T is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flow Coverage Ratios of ImmunovantInc are associated (or correlated) with its Net Income Per E B T. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per E B T has no effect on the direction of Cash Flow Coverage Ratios i.e., ImmunovantInc's Cash Flow Coverage Ratios and Net Income Per E B T go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Cash Flow Coverage Ratios
Net Income Per E B T
Most indicators from ImmunovantInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunovantInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.At this time, ImmunovantInc's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 78.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 30.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 156.0M | 208.3M | 239.5M | 123.8M | Research Development | 101.8M | 160.3M | 184.3M | 98.9M |
ImmunovantInc fundamental ratios Correlations
Click cells to compare fundamentals
ImmunovantInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmunovantInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 109.4M | 412.5M | 515.6M | 405.8M | 466.7M | 264.7M | |
Total Current Liabilities | 15.3M | 18.8M | 44.5M | 43.3M | 49.8M | 52.3M | |
Total Stockholder Equity | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 241.3M | |
Net Tangible Assets | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 242.7M | |
Accounts Payable | 1.2M | 2.4M | 18.6M | 1.4M | 1.6M | 1.5M | |
Common Stock Shares Outstanding | 43.2M | 87.8M | 109.7M | 123.1M | 141.5M | 148.6M | |
Other Stockholder Equity | 185.3M | 590.4M | 824.8M | 928.0M | 1.1B | 1.1B | |
Total Liab | 15.3M | 21.0M | 45.7M | 43.3M | 49.8M | 52.3M | |
Total Current Assets | 109.1M | 409.0M | 512.9M | 404.3M | 465.0M | 263.2M | |
Short Long Term Debt Total | 3.2M | 3.4M | 2.4M | 1.2M | 1.4M | 2.3M | |
Other Current Liab | 14.1M | 15.2M | 24.7M | 40.8M | 46.9M | 49.2M | |
Property Plant And Equipment Net | 65K | 3.5M | 2.6M | 1.5M | 1.7M | 1.7M | |
Net Debt | (97.4M) | (396.7M) | (491.5M) | (375.3M) | (337.8M) | (354.7M) | |
Retained Earnings | (91.2M) | (198.7M) | (355.4M) | (566.3M) | (509.7M) | (484.2M) | |
Cash | 100.6M | 400.1M | 493.8M | 376.5M | 433.0M | 301.7M | |
Non Current Assets Total | 311K | 3.5M | 2.6M | 1.5M | 1.7M | 1.8M | |
Cash And Short Term Investments | 100.6M | 400.1M | 493.8M | 376.5M | 433.0M | 301.7M | |
Net Receivables | 3.0M | 548K | 12.9M | 885K | 1.0M | 966.9K | |
Common Stock Total Equity | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Liabilities And Stockholders Equity | 109.4M | 412.5M | 515.6M | 405.8M | 466.7M | 317.6M | |
Non Current Liabilities Total | 14.1M | 2.2M | 1.2M | 47K | 42.3K | 40.2K | |
Capital Surpluse | 185.3M | 590.4M | 824.8M | 928.0M | 1.1B | 556.3M | |
Other Current Assets | 5.5M | 8.3M | 6.3M | 26.9M | 31.0M | 32.5M | |
Net Invested Capital | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 290.0M | |
Capital Stock | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Net Working Capital | 93.8M | 390.2M | 468.4M | 361.0M | 415.2M | 288.9M | |
Short Term Debt | 3.2M | 1.2M | 1.1M | 1.2M | 1.1M | 1.1M | |
Common Stock | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Property Plant Equipment | 65K | 201K | 330K | 333K | 383.0K | 216.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Transaction History View history of all your transactions and understand their impact on performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
CEOs Directory Screen CEOs from public companies around the world |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.